Retinal Research Institute – Phoenix
Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.
We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions
Mission / Purpose
Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.
News
Keep up with new research and findings from recent studies and trials.
Current Studies & Trials
Find out what current studies and trials we are enrolling for.
Interested in a Clinical Trial?
If you or someone you know is interested in more information about our clinical research trials, please contact us.
Pravin U. Dugel MD: Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema
/ Uncategorized /by retinalconsultantsPresented in part at: 15th Annual Angiogenesis, Exudation, and Degeneration meeting, February 2018, Miami, Florida; 41st Annual Macula Society Meeting, February 2018, Beverly Hills, California; Association for Research in Vision and Ophthalmology Annual Meeting, April–May 2018, Honolulu, Hawaii; Royal College of Ophthalmologists Annual Congress 2018, May 2018, Liverpool, United Kingdom; 36th World Ophthalmology Congress, June […]
Pravin U. Dugel, MD – Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
/ Uncategorized /by retinalconsultantsInitial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented PALO ALTO, Calif., July 24, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented […]